The Department of Justice has started investigating whether drug makers failed to disclose information about a possible carcinogen in versions of a popular heartburn drug called ranitidine, most commonly known as Zantac, that were sold to the U.S. government.

Two companies — Sanofi (SNY) and GlaxoSmithKline (GSK) — disclosed in securities filings last week that they received so-called civil investigative demands in June for information indicating potential violations of the False Claims Act, which suggests authorities are probing whether the drug makers submitted false claims to government agencies for reimbursement.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Wasn’t Sanofi the same company that solved the Dengvaxia that causes a lot of death in the Philippines.

    It seems next time I buy any medicine I have to make sure they are not from Sanofi given their questionable business ethics.

  • Could this civil action be a way to generate a rebate for this item from last Friday’s Pharmalitte? “The U.S. government’s Operation Warp Speed effort will provide up to $2.1 billion to Sanofi (SNY) and GlaxoSmithKline (GSK) to fund development and manufacturing of their experimental Covid-19 vaccine.”
    But I’m sure it’s all in the eyes of the Observer?

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy